Core Insights - The article highlights the top and bottom AH share premium rates, with Northeast Electric (00042) leading at 918.87% and Ningde Times (03750) at -17.09% [1][2] Summary by Category Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 918.87% with a deviation value of 109.61% [2] - Hongye Futures (03678) follows with a premium rate of 246.28% and a deviation value of 16.95% [2] - Zhejiang Shibao (01057) ranks third with a premium rate of 241.04% and a deviation value of 19.03% [2] Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -17.09% with a deviation value of -2.80% [2] - Heng Rui Pharmaceutical (01276) has a premium rate of -1.38% and a deviation value of 1.69% [2] - China Merchants Bank (03968) has a premium rate of 0.51% with a deviation value of -4.32% [2] Top AH Share Deviation Values - Northeast Electric (00042) leads with a deviation value of 109.61% [2] - Changfei Optical Fiber (06869) has a deviation value of 31.51% [2] - Shandong Molong (00568) follows with a deviation value of 26.68% [2] Bottom AH Share Deviation Values - Shanghai Electric (02727) has the lowest deviation value at -25.42% [3] - China National Foreign Trade Transportation Group (00598) has a deviation value of -16.00% [3] - COSCO Shipping Energy Transportation (01138) has a deviation value of -14.18% [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 中 國，北 京 2025年10月17日 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 董事會召開日期 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2025年10月30日（星 期 四）舉 行 董 事 會 會 議，以 考慮及通過（其 中 包 括）本集團截至2025 年9 月30日止九個月之第三季度業績及 其 發 佈。 JOINN LABORATORIES (CHINA) CO., LTD. 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫 雲 霞 女 ...

Core Viewpoint - Zhaoyan New Drug (06127.HK) has announced a board meeting scheduled for October 30, 2025, to consider and approve the third quarter performance for the nine months ending September 30, 2025, along with its release [1] Summary by Category - Company Announcement - The company will hold a board meeting on October 30, 2025, to discuss the third quarter results [1] - The performance report will cover the period ending September 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司（「本公司」及其附屬公司統稱為「本集團」） 之董事會（「董事會」）兹通告謹定於2025年10月30日（星 期 四）舉 行 董 事 會 會 議，以 考慮及通過（其 中 包 括）本集團截至2025 年9 月30日止九個月之第三季度業績及 其 發 佈。 承董事會命 北京昭衍新藥研究中心股份有限公司 主 席 馮宇霞 中 國，北 京 2025年10月17日 於 本 公 告 日 期，董 事 會 包 括 主 席 兼 執 行 董 事 馮 宇 霞 女 士、執 行 董 事 高 大 鵬 先 生、孫 雲 霞 女 士、羅 樨 女 士 及 顧 靜 良 先 生，及 獨 立 非 執 行 董 事 張 帆 先 生、楊 福 全 先 生、陽 昌 雲 先 生 及 應 放 天 先 生。 ...

Group 1 - A-shares and Hong Kong stocks in the innovative pharmaceutical sector have rebounded, with significant gains in related stocks and ETFs [1][3][5] - The largest medical ETF in A-shares (512170) saw a trading volume of 589 million yuan, recovering 1.34% on the day [1] - The innovative drug sector is experiencing a collective rise, with notable stocks like Huahai Pharmaceutical increasing by 7.59% [3] Group 2 - The Hong Kong innovative drug ETF (520880) rose by 2.12%, with 35 out of 37 constituent stocks gaining, led by Green Leaf Pharmaceutical with an 8.31% increase [5][7] - Recent funding trends indicate a significant inflow into the innovative drug sector, with over 1.29 billion yuan added in the last three days [7] - Upcoming catalysts include the European Society for Medical Oncology (ESMO) annual meeting, which may showcase significant research results from Chinese innovative drugs [7] Group 3 - Investment strategies suggest focusing on innovative drugs, with specific ETFs like the Hong Kong innovative drug ETF (520880) and the A-share drug ETF (562050) highlighted for their potential [8] - The medical ETF (512170) is noted for its inclusion of CXO companies, which account for 26.77% of its weight [8] - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9]

Core Viewpoint - Zhaoyan New Drug (603127) has seen a stock increase of over 3%, currently trading at 19.87 HKD, following the FDA's approval of YK012 for clinical trials, marking a significant milestone in the treatment of primary membranous nephropathy (pMN) [1] Company Summary - YK012, a bispecific antibody targeting CD19/CD3, has received IND approval from the FDA, making it the first T cell engager (TCE) drug approved for this indication globally [1] - Zhaoyan New Drug is a non-clinical CRO partner for YK012, participating in pharmacokinetic services and toxicology testing during the non-clinical trial phase [1] - The development of YK012 is supported by a dual-center strategy involving Excyte LLC, a wholly-owned subsidiary in the U.S., and the Beijing headquarters of Yikost [1] Industry Summary - The FDA's approval of YK012 represents a breakthrough for Chinese-origin bispecific antibody technology in the field of autoimmune diseases, achieving a synchronized advancement with the U.S. [1] - Following the IND approval, the company plans to initiate international multi-center clinical studies, complementing ongoing multi-center trials in China led by Professor Zhao Minghui from Peking University First Hospital [1]

Core Viewpoint - Zhaoyan New Drug (06127) has seen a stock price increase of over 3%, currently trading at 19.87 HKD, following the FDA's approval of YK012 for clinical trials, marking a significant milestone in the development of innovative therapies for primary membranous nephropathy (pMN) [1] Group 1: Company Developments - YK012, a bispecific antibody targeting CD19/CD3, has received IND approval from the FDA for treating pMN, making it the first T cell engager (TCE) bispecific antibody approved for this indication globally [1] - Zhaoyan New Drug is a non-clinical CRO partner for YK012, participating in pharmacokinetic services and toxicology testing during the non-clinical trial phase [1] Group 2: Research and Development Strategy - The development of YK012 is supported by a dual-center strategy with a headquarters in Beijing and a wholly-owned subsidiary, Excyte LLC, in the United States [1] - Following the FDA IND approval, the company plans to initiate international multi-center clinical studies, complementing ongoing multi-center trials in China led by Professor Zhao Minghui from Peking University First Hospital, to accelerate global research progress [1]

10月14日，昭衍新药盘中上涨2.02%，截至09:42，报33.26元/股，成交9405.17万元，换手率0.45%，总 市值249.28亿元。 资金流向方面，主力资金净流出425.62万元，特大单买入134.46万元，占比1.43%，卖出274.55万元，占 比2.92%；大单买入1200.14万元，占比12.76%，卖出1485.66万元，占比15.80%。 昭衍新药今年以来股价涨100.36%，近5个交易日跌5.81%，近20日跌4.01%，近60日涨27.38%。 今年以来昭衍新药已经3次登上龙虎榜，最近一次登上龙虎榜为9月15日。 资料显示，北京昭衍新药研究中心股份有限公司位于北京市经济技术开发区荣京东街甲5号,香港铜锣湾 希慎道33号利园1期19楼1920室，成立日期1998年2月25日，上市日期2017年8月25日，公司主营业务涉 及以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。 昭衍新药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：CRO概念、细胞治 疗、融资融券、中盘、专精特新等。 截至6月30日，昭衍新药股东户数6.12万，较上期 ...

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, indicating which companies saw the largest increases and decreases in ownership percentages over recent trading days [1][2]. Summary by Category Recent Changes in Holdings - Xinyi Energy (03868) saw an increase of 0.07% in its Hong Kong Stock Connect holding percentage, bringing the total to 12.98% [2]. - The Yingfu Fund (02800) increased by 0.05%, now at 2.10% [2]. - Haier Smart Home (06690) increased by 0.02%, with a current holding of 16.62% [2]. - Horizon Robotics-W (09660) experienced the largest decrease, with a drop of 0.82%, now at 14.69% [2]. - Southern Hang Seng Technology (03033) decreased by 0.63%, now at 59.30% [2]. - WuXi AppTec (02359) saw a decrease of 0.56%, with a current holding of 15.03% [2]. Five-Day Changes - The largest increase over the last five trading days was for Da Zhong Public Utilities (01635), which rose by 3.98% to 67.37% [3]. - Zhong Chuang Innovation (03931) increased by 1.40%, now at 17.08% [3]. - Zhaoyan New Drug (06127) rose by 1.08%, with a holding of 50.59% [3]. - The largest decrease was for Southern Hang Seng Technology (03033), which fell by 2.01% to 59.30% [3]. - Haotian International Construction (01341) decreased by 1.58%, now at 58.50% [3]. Twenty-Day Changes - Da Zhong Public Utilities (01635) had the most significant increase over the past twenty days, rising by 34.46% to 67.37% [4]. - Canggang Railway (02169) increased by 31.45%, now at 43.11% [4]. - Shanga Holdings (00412) rose by 13.53%, with a current holding of 15.00% [4].

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of October 9, with Northeast Electric (00042) leading at a premium of 743.75% [1][2]. AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): 743.75% - Andeli Juice (02218): 235.25% - Zhejiang Shibao (01057): 227.36% [1][2] - The bottom three stocks with the lowest AH premium rates are: - Contemporary Amperex Technology (03750): -16.12% - Heng Rui Medicine (01276): -2.39% - China Merchants Bank (03968): 3.49% [1][2] Deviation Values - The stocks with the highest deviation values are: - Changfei Optical Fiber (06869): 28.93% - Zhejiang Shibao (01057): 12.23% - Red Star Macalline (01528): 11.20% [1][2] - The stocks with the lowest deviation values are: - Northeast Electric (00042): -72.24% - Shanghai Electric (02727): -54.73% - Dazhong Public Utilities (01635): -29.80% [1][2]